Optimizing Care for Patients with Myelodysplastic Syndrome (MDS)

Optimizing Care for Patients with Myelodysplastic Syndrome (MDS)

French Subtitles Available in Video Player

Download Transcript (EN)
Download Transcript (FR)
Icon Objectives

Learning Objectives

  1. Characterize the current treatment landscape in defining the applicability of emerging trial outcomes in Canadian practice
  2. Share Key Opinion Leader best practices for implementation of novel treatment selection and management into clinical practice
  3. Improve outcomes for patients with MDS
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Rena Buckstein

Icon Chair Speaker

Speakers

Dr. Heather Leitch

Dr. Brett Houston

Studies / Trials Discussed

“Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

Oral Decitabine/Cedazuridine With Venetoclax Versus Oral Decitabine/Cedazuridine In High-risk Myelodysplastic Syndrome: A Propensity Score Matched Analysis

Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study”

This program has been made possible through unrestricted support from Taiho

Studies/trials discussed:

“Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents Oral Decitabine/Cedazuridine With Venetoclax Versus Oral Decitabine/Cedazuridine In High-risk Myelodysplastic Syndrome: A Propensity Score Matched Analysis Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study”
Tagged